Business / Finance

RSS

Bristol-Myers Squibb agrees purchase of Inhibitex for $2.5Bn

American pharmaceutical giant Bristol-Myers Squibb has agreed the purchase of US biotech company Inhibitex, in a $2.5Bn (£1.6bn) deal which includes the promising new anti-hepatitis C drug INX-189, first designed and prepared in Cardiff University.

19 Jan 2012

Courtagen announces acquisition of Medicinal Genomics

Courtagen Life Sciences, Inc.

From Beckman Coulter Life Sciences - Automation and Genomics 18 Jan 2012

RaNA Therapeutics completes $20.7 million round of financing

RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA.

18 Jan 2012

US BioDesign introduces new cardiovascular biomaterials business unit

US BioDesign announced today the launch of its cardiovascular biomaterials business segment. This portion of US BioDesign will be responsible for the research, analysis and production of products and services in the cardiovascular device area.

18 Jan 2012

Actavis, Scil Proteins sign Reteplase supply agreement

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase.

17 Jan 2012

Premier, Horizon enter three-year national group purchasing contract

Horizon Software International, the leader in K-12 food service technology and online account management, has been awarded a three-year national group purchasing contract with the Premier healthcare alliance.

17 Jan 2012

FUJIFILM commences tender offer for outstanding shares of SonoSite

FUJIFILM Holdings Corporation, a diversified technology company that operates in healthcare, highly functional materials, and document solutions, announced today the commencement of a tender offer through its indirect wholly-owned U.S. subsidiary Salmon Acquisition Corporation for all outstanding shares of common stock of SonoSite, Inc. for $54 per share, net to the seller in cash, without interest and less any required withholding taxes.

17 Jan 2012

Mentor executes long-term funding agreement to receive 50% ownership in Brighter Day Health

Mentor Capital, Inc. announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval.

17 Jan 2012

Newtricious secures backing of a consortium of investors

Life Sciences company Newtricious has secured the backing of a consortium of investors who will help it to continue to develop its first products focusing on the maintenance of health in people at risk for chronic diseases such as macular degeneration and cardiovascular illnesses.

17 Jan 2012

Rainbow Coral joins forces with BioHouston

Rainbow Coral Corp. positioned itself at the cutting edge of biotechnology innovation today by joining forces with BioHouston, Inc., one of the nation's preeminent drivers of life sciences research and commercialization.

13 Jan 2012

CrystalGenomics raises KRW 3 billion in private placement

CrystalGenomics, Inc., a clinical stage biopharmaceutical company headquartered in Korea, has just announced that it has successfully raised KRW 3 Billion (USD 2.6 Million) in a private placement to the Korea Seoul Life Science Fund.

13 Jan 2012

GC-Rise presents at J.P. Morgan's 30th annual Healthcare Conference

GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has debuted at J.P. Morgan's 30th annual Healthcare Conference in the United States.

13 Jan 2012

U.S. HealthWorks announces acquisition of Priority Medical Care

U.S. HealthWorks, a leading operator of occupational healthcare centers nationwide, today announced the acquisition of Priority Medical Care, operator of two medical clinics in Bridgewater and Somerset.

12 Jan 2012

Merger Sub II completes tender offer for outstanding shares of Pharmasset common stock

Gilead Sciences, Inc. today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc., for all of the outstanding shares of common stock of Pharmasset, Inc. a price of $137 per share, net to the seller in cash.

12 Jan 2012

Arena agrees to sell 9,953,250 shares of common stock

Arena Pharmaceuticals, Inc. announced today that it has agreed to sell 9,953,250 shares of its common stock, at a price of $1.65775 per share, and approximately 9,953 shares of its Series D Convertible Preferred Stock, at a price of $1,657.75 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization.

11 Jan 2012

Telormedix raises 7.5 million CHF

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors Aravis Venture and Proquest Investments.

10 Jan 2012

Cardio3BioSciences raises €3.1M in non-dilutive funding

The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.

10 Jan 2012